These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8882924)

  • 1. Management of hot flushes due to endocrine therapy for prostate carcinoma.
    Smith JA
    Oncology (Williston Park); 1996 Sep; 10(9):1319-22; discussion 1324. PubMed ID: 8882924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing hot flushes in men after prostate cancer--a systematic review.
    Frisk J
    Maturitas; 2010 Jan; 65(1):15-22. PubMed ID: 19962840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.
    Smith JA
    J Urol; 1994 Jul; 152(1):132-4. PubMed ID: 8201642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].
    Kliesch S; Behre HM; Roth S
    Dtsch Med Wochenschr; 1997 Jul; 122(30):940-5. PubMed ID: 9280708
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hot flushes in men after surgical or pharmacologic castration].
    Aubert J; Vigouroux V; Doré B
    Prog Urol; 1995 Sep; 5(4):507-9. PubMed ID: 7581499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recurrence of cancer of the prostate after initial treatment with diethylstilbestrol (DES) in a homogeneous series of 175 cases].
    Reziciner S
    Ann Urol (Paris); 1997; 31(4):213-24. PubMed ID: 9412346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone.
    Atala A; Amin M; Harty JI
    Urology; 1992 Feb; 39(2):108-10. PubMed ID: 1736500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary excretion of calcitonin gene-related peptide in males with hot flushes after castration for carcinoma of the prostate.
    Wyon Y; Spetz AC; Hammar M; Theodorsson E; Varenhorst E
    Scand J Urol Nephrol; 2001 Apr; 35(2):92-6. PubMed ID: 11411665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
    Reis LO; Zani EL; García-Perdomo HA
    Int Urol Nephrol; 2018 Jun; 50(6):993-1003. PubMed ID: 29600433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma].
    Suzuki K; Kobayashi M; Tokue A
    Nihon Hinyokika Gakkai Zasshi; 2003 Sep; 94(6):614-20. PubMed ID: 14531271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer.
    Gerber GS; Zagaja GP; Ray PS; Rukstalis DB
    Urology; 2000 Jan; 55(1):97-101. PubMed ID: 10654902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer.
    Miller JI; Ahmann FR
    Urology; 1992 Dec; 40(6):499-502. PubMed ID: 1281587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of diethylstilbestrol in the management of advanced prostate cancer.
    Bosset PO; Albiges L; Seisen T; de la Motte Rouge T; Phé V; Bitker MO; Rouprêt M
    BJU Int; 2012 Dec; 110(11 Pt C):E826-9. PubMed ID: 22578092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot flushes: mechanism and prevention.
    Radlmaier A; Neumann F; Bormacher K
    Prog Clin Biol Res; 1989; 303():89. PubMed ID: 2675021
    [No Abstract]   [Full Text] [Related]  

  • 17. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
    Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing hot flashes in men being treated for prostate cancer.
    Baum NH; Torti DC
    Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ST52 treatment of cancer of the prostate during the hormonal resistance phase].
    Grise P; Mnif A; Navarra S; Foulatier O; Barret E; Sibert L; Pfister C
    Ann Urol (Paris); 1998; 32(1):39-44. PubMed ID: 9559075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.